• Skip to content
  • Skip to navigation
  • Skip to footer
AstraZeneca logo AstraZeneca logo
AstraZeneca logo AstraZeneca logo
  • What science can do
  • R&D
    • R&D
    • Our approach
    • Transformative science
    • Data science & AI
    • Digital health
    • Our technologies
    • Next generation therapeutics
    • Publications
    • R&D strategic centres
  • Our therapy areas
    • All therapy areas
    • Oncology
    • BioPharmaceuticals
    • Cardiovascular, Renal and Metabolism
    • Respiratory & Immunology
    • Rare Disease
    • Other disease areas
    • Pipeline
    • All medicines
  • Our company
    • Our company
    • Our strategy
    • Our people
    • Our commitment to patients
    • Our leadership
    • Cambridge
    • Gothenburg
    • Gaithersburg
  • Careers
  • Investors
    • Investor Relations (Global) UK flag
    • Investor Relations (Sweden) Swedish flag
    • Resources
    • Governance
    • Shareholder information
    • Dividend policy
    • Key facts
    • FAQs
    • Debt Investors
    • ADR Programme
  • Media
    • Press Releases
    • Media centre
    • Statements
    • Articles
    • Image library
    • COVID-19 resources
    • Broadcast videos
    • Archive
    • Media contacts
  • Sustainability
    • Sustainability
    • Access to healthcare
    • Environmental protection
    • Ethics and transparency
    • Partnerships, alliances and recognition
    • Supporting our communities
    • Resources
  • Partnering
    • Partnering with AstraZeneca
    • Our Partnering teams
    • Our areas of partnering interest
    • Why partner with AstraZeneca?
    • Secrets to successful partnering
    • Supplier Information
    • A Catalyst Network
  • AstraZeneca Websites
  • Global site

澳洲幸运8开奖结果直播 官方app手机版直播视频

Read more

Article

Sustainable Markets Initiative Health Systems Taskforce

What science can do

Discovering novel genetic targets for fatty liver disease

Discover our dedication to being a great place to work

We have

183

projects in our pipeline

View pipeline

COVID-19 Information Hub

Our Cambridge site (UK) is one of AstraZeneca's three global science centres

Explore all our science centres

Our Sustainability ambition

Corporate Press Release

PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma

15 May 2022
Corporate Press Release

Human ventricular progenitor cells promote the formation of new heart tissue following a heart attack

12 May 2022

AstraZeneca Websites

This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network.



Date of next review: August 2022

Resources

  • All resources
  • Open Innovation
  • Externally sponsored scientific research
  • Medical Information for HCPs
  • US prescription assistance programmes
  • Global clinical trials information
  • Medicines
  • Report a possible side effect

Quick links

  • Media
  • Investor Relations
  • Partnering
  • Careers
  • Sustainability
  • Modern Slavery Statement
  • AZethics – Report A Concern
  • Supplier information
  • Social Media Community Guidelines

Social Media

  • YouTube
  • Instagram
  • Glassdoor
  • Facebook

utility links

  • Legal notice and Terms of Use
  • Privacy notice
  • Site map
  • Contact us
  • Cookie policy

© AstraZeneca 2022

开奖网站 香港6合和彩生肖数字2022 澳门六盒宝典2022年最新版开奖 极速6合5分钟官网 一分钟极速赛车开奖网 sg飞艇开奖直播网 幸运飞行艇168彩票开奖官方 2022极速飞艇168官网 澳洲幸运5开奖号码结果 澳洲幸运8开奖直播官方 澳洲幸运10开奖直播 台湾大乐透官方网站开奖结果 PC蛋蛋幸运28在线直播开奖结果 河内5分彩越南官方开奖网